Does rehabilitation help SMA type I?

Yes, and especially — in combination with disease-modifying therapy (nusinersen, Zolgensma, risdiplam). The drugs restore motor neuron function, but without targeted exercise and physiotherapy a correct movement pattern is not formed, and contractures and respiratory problems remain. The modern approach is therefore drug + regular rehabilitation, and outcomes in SMA type I children today are radically different from those of 10 years ago.

Can it be combined with nusinersen?

Not only can — but should. Rehabilitation and drugs are two layers of one strategy, they work in parallel. We receive a discharge note from the treating neurologist with the nusinersen / onasemnogene / risdiplam administration protocol, align the rehabilitation course load with injection or infusion schedules, and coordinate any changes in condition. There is no conflict between the methods.

What is the prognosis for type III?

SMA type III (Kugelberg-Welander disease) is the mildest of the classic forms. Onset after 18 months, ambulation usually preserved in childhood but gradually lost by adolescence or adulthood. With modern therapy and regular rehabilitation ambulation can be preserved much longer, sometimes lifelong. The program goal is to maintain mobility, prevent scoliosis and contractures, and train the respiratory muscles.

SMA

Treatment of SMA in

Name: Нейролайф Китай
Price range: $$

SMA rehabilitation at NeuroLife Huizhou is about maintaining motor function, respiratory musculature, and quality of life in parallel with modern drug therapy (nusinersen Spinraza, onasemnogene Zolgensma, risdiplam Evrysdi). The program combines specialized therapeutic exercise, physiotherapy, breathing gymnastics, and traditional Chinese medicine approaches to support immunity — frequent infections remain the main risk factor in types I–II.

Стабилизация и сдвиг по моторным шкалам

improvement

—

patients

2–3 months + long-term maintenance

course

About the condition

What is Spinal Muscular Atrophy (SMA)?

Spinal muscular atrophy (SMA) is an autosomal recessive hereditary disease that damages motor neurons in the anterior horns of the spinal cord. The underlying cause is a mutation in the SMN1 gene on chromosome 5 (5q13.2) leading to a deficit of the SMN protein critical for motor neuron survival. ICD-10 code G12.0 (SMA type I) with subtypes spanning G12.0–G12.9. Incidence — 1 in 6000–10000 newborns, carrier rate 1 in 50. SMA is classified by age of onset and maximum achieved motor function: type 0 (prenatal), type I / Werdnig-Hoffmann (onset before 6 months, never sit), type II (6–18 months, sit but do not walk), type III / Kugelberg-Welander (>18 months, walk and then lose function), type IV (adult onset). In the last 5–7 years the SMA treatment landscape has been transformed: three disease-modifying drugs have appeared — the antisense oligonucleotide nusinersen (Spinraza), the gene therapy onasemnogene (Zolgensma, single infusion for children under age 2), and the oral splicing modifier risdiplam (Evrysdi). All three significantly change the prognosis. By themselves, however, the drugs do not restore already lost motor skills and do not solve problems with contractures, scoliosis, or respiratory failure. Rehabilitation remains critically important, which is why families travel to Huizhou. Our program includes several streams. Therapeutic exercise — individually tailored gentle exercises to maintain joint mobility, prevent contractures, and train available motor functions. Breathing gymnastics — critical in types I–II: diaphragm and intercostal training, special effective-cough techniques to prevent aspiration pneumonias. Physiotherapy — to maintain muscle trophism. Occupational therapy — adapting the home environment, selecting aids (orthoses, support seating, respiratory equipment). A special part of the Huizhou program is traditional Chinese medicine for immunity. Gentle acupuncture, herbal baths, individual herbal formulas to strengthen general state. In children with SMA types I–II recurrent infections are the main cause of hospitalizations and complications, and any immunity support directly affects quality and length of life. Coordination with the treating neurologist and pulmonologist is mandatory — we work alongside, not instead of, the core medical team.

Causes

Autosomal recessive mutation of the SMN1 gene on chromosome 5 (5q13.2). In 95% of patients — a homozygous deletion of SMN1 exon 7; in the rest — a combination of deletion and point mutation. Phenotype severity is determined by the number of copies of the backup SMN2 gene — the more copies, the milder the course. With a family case, carrier screening is recommended when planning the next pregnancy.

Symptoms

Progressive symmetric proximal muscle weakness, hypotonia (floppy baby in type I), areflexia, tongue fasciculations (a hallmark of type I), motor delay or regression. Cognition and sensation are preserved — an important diagnostic feature. In severe forms — swallowing difficulties, respiratory failure, the typical frog-leg posture with abducted hips and bell-shaped chest.

Diagnostics

The gold standard is genetic testing of SMN1 (exon 7 deletion analysis) and SMN2 copy number determination (for prognosis and gene therapy decisions). Additional steps — EMG (characteristic denervation pattern), nerve conduction (normal), CK level (usually normal or slightly elevated — unlike DMD). For motor function — the CHOP-INTEND scale (for type I) or HFMSE (for II–III). For respiratory issues — spirometry, cough effectiveness assessment.

Prognosis

Disease-modifying drugs have changed the landscape. Without therapy in type I — lethality before age 2 from respiratory complications; with nusinersen or Zolgensma — significant motor improvement and life extension, children start sitting, sometimes standing. In types II–III timely drug therapy plus regular rehabilitation maximally slow progression and preserve function. Early intervention (via newborn screening with a family case) yields the best outcome.

Our approach